Medpace Holdings

▲ Bull Case

• ◆GLP-1/obesity wave produces step-change in metabolic backlog. ClinicalTrials.gov has 3x as many obesity/MASH trials registered today vs. 2020, and Medpace's metabolic-disease expertise positions it to capture disproportionate share. If metabolic grows from ~17% to 25%+ of backlog by FY2027, that segment alone could add $200–400M to backlog per year, lifting revenue growth back to 13%+ and EBITDA margin to 28%+ on operating leverage. Bull-case price: $560–$620 (+25–38%).
• ◆Buyback amplification compounds even in slow-growth world. At ~$450 and ~28.6M shares, MEDP generates ~$565M FCF (FY2026E) — a 4.4% FCF yield. Deploying $400–500M/yr to buybacks retires 3–3.5% of share count annually, adding 3pp to per-share EPS growth even with modest revenue growth. EPS still compounds at ~13% CAGR through FY2030 under the base case.
• ◆Founder alignment and capital discipline are best-in-class. Troendle owns ~20%, has 30+ years tenure, refuses M&A, executes systematic buybacks, and runs the business with scientific (not financial-engineering) priority. This combination is rare; sophisticated long-duration investors should pay a quality premium for it.

▼ Bear Case

• ◆Q1 2026 book-to-bill 0.88x signals a fresh deceleration leg, not noise. Backlog of ~$3.5–3.7B provides 1.4-year revenue coverage, but if book-to-bill stays below 1.0x for 2+ more quarters, FY2027 revenue growth could be sub-5% — well below the 9% base-case assumption. Combined with multiple compression to peer parity (10–12x EV/EBITDA), bear-case price = $260–$330 (-27% to -42%).
• ◆The 22% EBITDA margin guide for FY2026 may be the new normal, not a one-year anomaly. Wage inflation in scientific labor, technology investment to compete with IQVIA's platforms, and competitive pricing pressure from ICLR's small-biotech push could prevent the margin from recovering to 26%+. If 22-24% is structural, the variant bull-case operating-leverage story is dead.
• ◆Premium valuation prices out the safety net. At 20.4x forward EV/EBITDA vs. 10x ICLR, MEDP needs to outgrow ICLR by ~7pp/year sustainably to justify the premium. The Q1 2026 weak book-to-bill weakens that argument.

“The Street debate centers on whether Q1 2026 cancellation pressure is signal or noise. Bulls (Stifel, Jefferies) argue cancellations are typically lumpy and reflect specific client funding distress that does not repeat. Bears (Morgan Stanley) argue the small-biotech segment is structurally weaker post-2022 — sustained higher cancellation rates are the new base. The secondary debate is whether 22% FY2026 EBITDA margin is transitory or structural — bulls expect reversion to 26%+ by FY2027; bears worry about wage inflation and technology investment pressure. The Street is roughly split 50/50; consensus FY2027 EPS of ~$19.50 and price target ~$480 implies modest upside.”

• ◆Q2/Q3 2026 book-to-bill recovery — if back above 1.05x for 2 consecutive quarters, multiple expansion possible
• ◆Large metabolic-disease program award — a multi-study GLP-1/MASH partnership could add $200–400M to backlog in one print
• ◆FY2027 EBITDA margin guide above 26% — would validate variant operating-leverage thesis
• ◆Biotech IPO market reopening — XBI sustained >100 historically correlates with MEDP book-to-bill acceleration 1-2 quarters later
• ◆Continued buyback execution at $400M+/yr pace — locks in share count reduction tailwind

• ◆Sustained book-to-bill below 1.0x — would imply backlog burn-down and FY2027 revenue decline
• ◆Margin compression sticking at 22-24% — invalidates the operating-leverage thesis
• ◆Troendle succession event — founder departure could trigger 10-20% multiple compression
• ◆Major client cancellation event — single large biotech bankruptcy could remove $100M+ from backlog
• ◆Multiple compression to peer parity — if 20.4x EV/EBITDA premium evaporates toward ICLR's 10x, equity value falls ~40% even at flat EBITDA
• ◆FDA regulatory disruption — reduced trial requirements or extended IND review delays from staffing cuts could affect demand